Capricor Therapeutics, Inc. (CAPR): Price and Financial Metrics


Capricor Therapeutics, Inc. (CAPR): $4.22

-0.03 (-0.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CAPR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CAPR Stock Price Chart Interactive Chart >

Price chart for CAPR

CAPR Price/Volume Stats

Current price $4.22 52-week high $6.58
Prev. close $4.25 52-week low $2.81
Day low $4.21 Volume 72,408
Day high $4.41 Avg. volume 123,060
50-day MA $4.02 Dividend yield N/A
200-day MA $4.50 Market Cap 106.52M

Capricor Therapeutics, Inc. (CAPR) Company Bio


Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company was founded in 2005 and is based in Beverly Hills, California.


CAPR Latest News Stream


Event/Time News Detail
Loading, please wait...

CAPR Latest Social Stream


Loading social stream, please wait...

View Full CAPR Social Stream

Latest CAPR News From Around the Web

Below are the latest news stories about CAPRICOR THERAPEUTICS INC that investors may wish to consider to help them evaluate CAPR as an investment opportunity.

Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients

-Statistically Significant Results in Performance of the Upper Limb PUL 2.0 (p=0.02) Extended to 18 Months, Demonstrating Long-Term Benefit in Skeletal Muscle Function- -Results Continue to Suggest Potential Disease Modification in Duchenne Muscular Dystrophy (DMD)- -Capricor to Host Webinar in Conjunction with Parent Project Muscular Dystrophy (PPMD) Today at 1:00 p.m. ET- SAN DIEGO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the d

Yahoo | January 25, 2023

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Provide Recent Updates on CAP-1002 Program

-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular dystrophy- -Webinar to be held on Wednesday, January 25, 2023 at 1:00 p.m. ET- SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today that the C

Yahoo | January 19, 2023

Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study

Capricor Therapeutics (NASDAQ: CAPR) announced the publication of a preclinical study online in bioRxiv and explored Capricor's proprietary StealthX exosome platform's therapeutic potential, generating two vaccine candidates (STX-S and STX-N). The vaccines independently and in combination (STX-S+N) induced a strong immune response against two SARS-CoV-2 proteins, spike and nucleocapsid. Results showed that this multivalent, protein-based vaccine candidate has the potential to achieve potent, lon

Yahoo | January 12, 2023

Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform

-StealthX™ Exosome Platform Shows Multivalent Vaccine Induces Long-Lasting Immunity to Multiple SARS-CoV-2 Proteins- SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today the publication of a preclinical study highlighting new advances for its engineered exosome program. The dat

Yahoo | January 12, 2023

Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?

Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | January 11, 2023

Read More 'CAPR' Stories Here

CAPR Price Returns

1-mo 9.33%
3-mo -16.93%
6-mo -10.78%
1-year 18.21%
3-year 175.82%
5-year -76.94%
YTD 9.33%
2022 31.74%
2021 -14.58%
2020 167.97%
2019 -68.78%
2018 -74.05%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6781 seconds.